Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 12/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3042545 | 0.99 | KEAP1 (0.46) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL3044724 | 0.88 | CHRM3 (0.44) | CHRM3CHRM2CHRM1SMN1; SMN2 | |
| SCHEMBL4886224 | 0.85 | KEAP1 (0.50) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL3049247 | 0.84 | KEAP1 (0.49) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL3049212 | 0.83 | CHRM2 (0.47) | CHRM3CHRM2CHRM1 | |
| SCHEMBL3034639 | 0.83 | ALDH1A1 (0.55) | CHRM3CHRM2CHRM1SMN1; SMN2ALDH1A1 | |
| SCHEMBL3050663 | 0.82 | CHRM2 (0.46) | CHRM3CHRM2CHRM1 | |
| SCHEMBL3044573 | 0.82 | POLB (0.55) | CHRM3CHRM2CHRM1SMN1; SMN2ALDH1A1 | |
| SCHEMBL3044988 | 0.82 | POLB (0.55) | CHRM3CHRM2CHRM1SMN1; SMN2ALDH1A1 | |
| SCHEMBL4890692 | 0.77 | SMN1; SMN2 (0.41) | CHRM3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280883-A1 | Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-11-13 | — | — | US | claimed |
| EP-1794161-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2007-06-13 | — | — | EP | claimed |
| WO-2006032994-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-03-30 | — | — | WO | claimed |
| US-20080280883-A1 | Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-11-13 | — | — | US | disclosed |
| EP-1794161-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006032994-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280883-A1 | Muscarinic Receptor Antagonists | CHRM3, CHRM5, CHRM2 | KEAP1 1713/4885NFE2L2 4205/4885CHRM3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.